Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aseem Anand

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancerMichael J Morris, Jessica Flynn, Binsheng Zhao, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
European Urology|August 2, 2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetateDaniel C Danila, Aseem Anand, Clifford C Sung, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Plos One|June 5, 2026
Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastasesJesus E Juarez Casillas, Maryam Nezafat, Cecil M Benitez, et al.
The Lancet. Oncology|October 13, 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective studyRobert W Ross, Matthew D Galsky, Howard I Scher, et al.
European Urology Focus|July 21, 2017
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical PracticeMariana Reza, Mattias Ohlsson, Reza Kaboteh, et al.
The Prostate|June 24, 2022
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancerTao Yang, Ying Liu, Shuzhen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancerDavid R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2025
Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancerMichael J Morris, Jessica Flynn, Binsheng Zhao, et al.
The Prostate|December 20, 2016
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate CancerAjjai Alva, Luke Nordquist, Stephanie Daignault, et al.
European Urology|August 2, 2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetateDaniel C Danila, Aseem Anand, Clifford C Sung, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Plos One|June 5, 2026
Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastasesJesus E Juarez Casillas, Maryam Nezafat, Cecil M Benitez, et al.
The Lancet. Oncology|October 13, 2012
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective studyRobert W Ross, Matthew D Galsky, Howard I Scher, et al.
European Urology Focus|July 21, 2017
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical PracticeMariana Reza, Mattias Ohlsson, Reza Kaboteh, et al.
The Prostate|June 24, 2022
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancerTao Yang, Ying Liu, Shuzhen Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancerDavid R Shaffer, Margaret A Leversha, Daniel C Danila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Pageof 4